10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q3 2020

Filing Information

Form Type	10-Q
Accession Number	`0001628280-20-015769`
Period End Date	20200930
Filing Date	20201105
Fiscal Year	2020
Fiscal Period	Q3
XBRL Instance	gh-20200930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 80 Cash Flow Statement 88 Stockholders Equity 50 Comprehensive Income 28

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$142.94M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$143.23M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$379.57M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$870.46M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$36.26M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$47.99M	USD	Point-in-time
Inventory	`InventoryNet`	$15.18M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$27.73M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$11.39M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$9.90M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	94.26M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	99.90M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$597.36M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.09B	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$51.40M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	99.90M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	94.26M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$268.78M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$43.67M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$61.88M	USD	Point-in-time
Assets	`Assets`	$1.26B	USD	Point-in-time
Assets	`Assets`	$962.53M	USD	Point-in-time
Liabilities	`Liabilities`	$113.50M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$29.14M	USD	Point-in-time
Liabilities	`Liabilities`	$114.54M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$36.10M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$16.64M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$8.52M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Capitalized license fees	`CapitalizedLicenseFees`	$50.00K	USD	Point-in-time
Capitalized license fees	`CapitalizedLicenseFees`	$6.89M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$5.45M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$4.88M	USD	Point-in-time
Total Assets	`Assets`	$1.26B	USD	Point-in-time
Total Assets	`Assets`	$962.53M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$18.28M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$16.20M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$24.04M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$18.56M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$22.31M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$25.70M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$12.28M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$7.34M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$72.73M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$71.97M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$39.68M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$33.26M	USD	Point-in-time
Obligation related to royalty	`AccruedRoyaltiesNoncurrent`	$6.88M	USD	Point-in-time
Obligation related to royalty	`AccruedRoyaltiesNoncurrent`	-	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.67M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.86M	USD	Point-in-time
Total Liabilities	`Liabilities`	$113.50M	USD	Point-in-time
Total Liabilities	`Liabilities`	$114.54M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$49.60M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$56.40M	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 99,897,188 and 94,261,414 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 99,897,188 and 94,261,414 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.60B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.15B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$3.86M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$1.11M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-352.81M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-512.85M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.09B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$815.47M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.11B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$815.40M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$483.15M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$962.53M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.26B	USD	Point-in-time

Income Statement 80 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$171.62M	USD	3 Qtrs
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$60.38M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$52.15M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$123.05M	USD	3 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$8.70M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$36.79M	USD	3 Qtrs
Development services and other	`RevenuefromDevelopmentServices`	$14.19M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$28.43M	USD	3 Qtrs
Total revenue	`Revenues`	$60.85M	USD	1 Quarter
Total revenue	`Revenues`	$208.41M	USD	3 Qtrs
Total revenue	`Revenues`	$74.57M	USD	1 Quarter
Total revenue	`Revenues`	$151.48M	USD	3 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$16.70M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$16.58M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$42.25M	USD	3 Qtrs
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$52.70M	USD	3 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$6.63M	USD	3 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$4.49M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$11.43M	USD	3 Qtrs
Cost of development services and other	`CostofDevelopmentServices`	$1.94M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$36.24M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$109.58M	USD	3 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$60.42M	USD	3 Qtrs
Research and development expense	`ResearchAndDevelopmentExpense`	$24.57M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$25.09M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$56.05M	USD	3 Qtrs
Sales and marketing expense	`SellingAndMarketingExpense`	$18.80M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$75.22M	USD	3 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$16.44M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$66.29M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$42.54M	USD	3 Qtrs
General and administrative expense	`GeneralAndAdministrativeExpense`	$123.27M	USD	3 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$207.89M	USD	3 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$78.33M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$372.20M	USD	3 Qtrs
Total costs and operating expenses	`CostsAndExpenses`	$148.82M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-163.78M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-74.25M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-56.41M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-17.48M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.29M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$8.27M	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$2.31M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$9.87M	USD	3 Qtrs
Interest expense	`InterestExpense`	$8.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$30.00K	USD	3 Qtrs
Interest expense	`InterestExpense`	$280.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$860.00K	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$179.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$275.00K	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$345.00K	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$2.42M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-71.60M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-47.12M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-153.12M	USD	3 Qtrs
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-13.29M	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$68.00K	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$116.00K	USD	3 Qtrs
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$-1.38M	USD	3 Qtrs
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$-202.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-13.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-45.74M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$4.70M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$6.80M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$6.00M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$-300.00K	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-160.04M	USD	3 Qtrs
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-12.79M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-77.67M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-50.44M	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.14	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.78	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.56	USD	3 Qtrs
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-1.66	USD	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.45M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	96.66M	shares	3 Qtrs
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	93.30M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	99.55M	shares	1 Quarter

Cash Flow Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-13.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-45.74M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$7.96M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$11.46M	USD	3 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$2.87M	USD	3 Qtrs
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$3.35M	USD	3 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	3 Qtrs
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	3 Qtrs
Unrealized translation gains (loss) on obligation related to royalty	`UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty`	$330.00K	USD	3 Qtrs
Unrealized translation gains (loss) on obligation related to royalty	`UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty`	-	USD	3 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	3 Qtrs
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-120.00K	USD	3 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$11.88M	USD	3 Qtrs
Non-cash stock-based compensation	`ShareBasedCompensation`	$87.35M	USD	3 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.64M	USD	3 Qtrs
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$1.95M	USD	3 Qtrs
Benefit from income tax differences	`IncreaseDecreaseInDeferredIncomeTaxes`	-	USD	3 Qtrs
Benefit from income tax differences	`IncreaseDecreaseInDeferredIncomeTaxes`	$1.24M	USD	3 Qtrs
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	-	USD	3 Qtrs
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-8.06M	USD	3 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-908.00K	USD	3 Qtrs
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-11.58M	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$12.55M	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$5.62M	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$453.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-491.00K	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$7.57M	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$1.04M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$846.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$426.00K	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$11.62M	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$5.48M	USD	3 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$6.37M	USD	3 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-1.51M	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-3.52M	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$600.00K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-4.94M	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-3.04M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-44.70M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-16.79M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$580.17M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$542.47M	USD	3 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$223.06M	USD	3 Qtrs
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$307.55M	USD	3 Qtrs
Business acquisition, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$7.33M	USD	3 Qtrs
Business acquisition, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$28.89M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$11.63M	USD	3 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$2.57M	USD	3 Qtrs
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-319.40M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-340.93M	USD	3 Qtrs
Payments made on royalty obligations	`PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations`	$228.00K	USD	3 Qtrs
Payments made on royalty obligations	`PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations`	-	USD	3 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$125.00K	USD	3 Qtrs
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$79.00K	USD	3 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$9.79M	USD	3 Qtrs
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$7.40M	USD	3 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$3.96M	USD	3 Qtrs
Proceeds from issuances of common stock under employee stock purchase plan	`ProceedsFromStockPlans`	$5.12M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	-	USD	3 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$355.73M	USD	3 Qtrs
Proceeds from public offering, net of underwriting discounts and commissions	`ProceedsFromIssuanceOfCommonStock`	$350.43M	USD	3 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$1.13M	USD	3 Qtrs
Payment of offering costs related to public offering	`PaymentsOfStockIssuanceCosts`	$811.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$364.23M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$363.58M	USD	3 Qtrs
Net effect of foreign exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$137.00K	USD	3 Qtrs
Net effect of foreign exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$239.00K	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-283.00K	USD	3 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$6.64M	USD	3 Qtrs
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$140.54M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$142.94M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$147.19M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$140.54M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$142.94M	USD	Point-in-time
Cash and cash equivalentsEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$147.19M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$9.70M	USD	3 Qtrs
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$10.46M	USD	3 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$6.42M	USD	3 Qtrs
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$4.30M	USD	3 Qtrs
Initial fair value of contingent consideration at acquisition date	`BusinessCombinationContingentConsiderationLiability`	-	USD	Point-in-time
Initial fair value of contingent consideration at acquisition date	`BusinessCombinationContingentConsiderationLiability`	$1.06M	USD	Point-in-time

Stockholders Equity 50 line items

Line Item	Tag	Value	Unit	Period
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	3 Qtrs
Adjustments to additional paid in capital, stock issued, issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$723.00K	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$300.00K	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-6.80M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-4.70M	USD	3 Qtrs
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-6.00M	USD	1 Quarter
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.09B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$815.47M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$815.40M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$483.15M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	4.31M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	5.17M	shares	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	3 Qtrs
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$349.71M	USD	3 Qtrs
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Point-in-time
Issuance of common stock in public offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$349.70M	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	1.19M	shares	3 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.40M	USD	3 Qtrs
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.26M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.85M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$9.79M	USD	3 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$39.00K	USD	3 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$82.00K	USD	3 Qtrs
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.96M	USD	3 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$5.12M	USD	3 Qtrs
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$3.19M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	3 Qtrs
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$2.25M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$87.35M	USD	3 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$55.20M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.48M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$11.88M	USD	3 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-1.53M	USD	1 Quarter
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$2.75M	USD	3 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$1.19M	USD	3 Qtrs
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-235.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-13.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-45.74M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.09B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$815.47M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.11B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$815.40M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$483.15M	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-13.09M	USD	1 Quarter
Net loss	`ProfitLoss`	$-153.24M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-45.74M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-71.67M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.72M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$2.51M	USD	3 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.05M	USD	3 Qtrs
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-282.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$137.00K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$47.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$239.00K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$191.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.53M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$2.75M	USD	3 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.19M	USD	3 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-235.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-73.20M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-44.55M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-150.49M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-13.32M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$4.70M	USD	3 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$6.00M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$6.80M	USD	3 Qtrs
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$-300.00K	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-49.25M	USD	3 Qtrs
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-13.03M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-79.20M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-157.29M	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.